Faculty of Pharmaceutical Sciences, Tokyo University of Science.
Kaede Pharmacy.
Yakugaku Zasshi. 2024;144(8):805-813. doi: 10.1248/yakushi.24-00016.
In Japan, the Pharmaceutical and Medical Device Act was amended in December 2019, and now requires pharmacists to follow-up on patients during treatment. Although there have been some studies on the effectiveness of follow-ups by pharmacists, there are no reports on the status of implementation in clinical practice. We conducted a nationwide survey on follow-up care to investigate the actual situation. We randomly selected 10% of community pharmacies in each prefecture and conducted a survey. We built a web-based system for the collection of basic information on the pharmacies and follow-up cases. A total of 561 pharmacies were pre-entered. Of these, 110 pharmacies (19.6%) reported 326 follow-up cases. Information was provided to doctors in 129 cases (39.6%), of which prescription proposals were made in 10 (7.8%) instances. The follow-up implementation rate based on the number of prescriptions dispensed was estimated to be 0.84% (95% confidence interval: 0.76-0.94%). This study revealed the status of follow-ups in clinical practice. Pharmacists can contribute to the optimization of drug treatment by providing follow-up information to doctors and making prescription proposals.
在日本,《药品和医疗器械法》于 2019 年 12 月修订,现在要求药剂师在治疗过程中对患者进行随访。虽然已经有一些关于药剂师随访效果的研究,但没有关于临床实践中实施情况的报告。我们进行了一项全国性的随访护理调查,以调查实际情况。我们随机抽取每个县的 10%的社区药店进行调查。我们建立了一个基于网络的系统,用于收集药店和随访病例的基本信息。共预录入了 561 家药店。其中,110 家(19.6%)药店报告了 326 例随访病例。在 129 例(39.6%)向医生提供了信息的病例中,有 10 例(7.8%)提出了处方建议。根据配药数量估计的随访实施率为 0.84%(95%置信区间:0.76-0.94%)。本研究揭示了临床实践中的随访现状。药剂师可以通过向医生提供随访信息和提出处方建议,为优化药物治疗做出贡献。